Does the clot burden as assessed by the Mean Bilateral Proximal Extension of the Clot score reflect mortality and adverse outcome after pulmonary embolism?

Computed tomography angiography pulmonary artery/diagnostic imaging pulmonary embolism/mortality retrospective studies risk assessment

Journal

Acta radiologica open
ISSN: 2058-4601
Titre abrégé: Acta Radiol Open
Pays: England
ID NLM: 101651010

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 19 12 2022
accepted: 24 06 2023
pubmed: 10 7 2023
medline: 10 7 2023
entrez: 10 7 2023
Statut: epublish

Résumé

Rapid diagnosis and risk stratification are important to reduce the risk of adverse clinical events and mortality in acute pulmonary embolism (PE). Although clot burden has not been consistently shown to correlate with disease outcomes, proximally located PE is generally perceived as more severe. To explore the ability of the Mean Bilateral Proximal Extension of the Clot (MBPEC) score to predict mortality and adverse outcome. This was a single center retrospective cohort study. 1743 patients with computed tomography pulmonary arteriography (CTPA) verified PE diagnosed between 2005 and 2020 were included. Patients with active malignancy were excluded. The PE clot burden was assessed with MBPEC score: The most proximal extension of PE was scored in each lung from 1 = sub-segmental to 4 = central. The MBPEC score is the score from each lung divided by two and rounded up to nearest integer. We found inconsistent associations between higher and lower MBPEC scores versus mortality. The all-cause 30-day mortality of 3.9% (95% CI: 3.0-4.9). The PE-related mortality was 2.4% (95% CI: 1.7-3.3). Patients with MBPEC score 1 had higher all-cause mortality compared to patients with MBPEC score 4: Crude Hazard Ratio (cHR) was 2.02 (95% CI: 1.09-3.72). PE-related mortality was lower in patients with MBPEC score 3 compared to score 4: cHR 0.22 (95% CI: 0.05-0.93). Patients with MBPEC score 4 did more often receive systemic thrombolysis compared to patients with MBPEC score 1-3: 3.2% vs. 0.6% ( We found no consistent association between the MBPEC score and mortality. Our results therefore indicate that peripheral PE does not necessarily entail a lower morality risk than proximal PE.

Sections du résumé

Background UNASSIGNED
Rapid diagnosis and risk stratification are important to reduce the risk of adverse clinical events and mortality in acute pulmonary embolism (PE). Although clot burden has not been consistently shown to correlate with disease outcomes, proximally located PE is generally perceived as more severe.
Purpose UNASSIGNED
To explore the ability of the Mean Bilateral Proximal Extension of the Clot (MBPEC) score to predict mortality and adverse outcome.
Methods UNASSIGNED
This was a single center retrospective cohort study. 1743 patients with computed tomography pulmonary arteriography (CTPA) verified PE diagnosed between 2005 and 2020 were included. Patients with active malignancy were excluded. The PE clot burden was assessed with MBPEC score: The most proximal extension of PE was scored in each lung from 1 = sub-segmental to 4 = central. The MBPEC score is the score from each lung divided by two and rounded up to nearest integer.
Results UNASSIGNED
We found inconsistent associations between higher and lower MBPEC scores versus mortality. The all-cause 30-day mortality of 3.9% (95% CI: 3.0-4.9). The PE-related mortality was 2.4% (95% CI: 1.7-3.3). Patients with MBPEC score 1 had higher all-cause mortality compared to patients with MBPEC score 4: Crude Hazard Ratio (cHR) was 2.02 (95% CI: 1.09-3.72). PE-related mortality was lower in patients with MBPEC score 3 compared to score 4: cHR 0.22 (95% CI: 0.05-0.93). Patients with MBPEC score 4 did more often receive systemic thrombolysis compared to patients with MBPEC score 1-3: 3.2% vs. 0.6% (
Conclusion UNASSIGNED
We found no consistent association between the MBPEC score and mortality. Our results therefore indicate that peripheral PE does not necessarily entail a lower morality risk than proximal PE.

Identifiants

pubmed: 37426515
doi: 10.1177/20584601231187094
pii: 10.1177_20584601231187094
pmc: PMC10328056
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20584601231187094

Informations de copyright

© The Author(s) 2023.

Déclaration de conflit d'intérêts

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Jostein Gleditsch (J)

Department of Radiology, Østfold Hospital, Kalnes, Norway.
Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway.

Øyvind Jervan (Ø)

Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway.
Department of Cardiology, Østfold Hospital, Kalnes, Norway.

Frederikus Klok (F)

Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.

René Holst (R)

Oslo Centre for Biostatistics and Epidemiology, University of Oslo and Oslo University Hospital, Oslo, Norway.

Einar Hopp (E)

Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.

Mazdak Tavoly (M)

Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Waleed Ghanima (W)

Internal Medicine Clinic, Østfold Hospital, Kalnes, Norway.
Department of Hematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Classifications MeSH